论文部分内容阅读
目的:探讨参麦注射液联合阿托伐他汀治疗急性心肌梗死临床疗效观察。方法:将符合标准的148例老年急性脑梗死患者随机分成观察组和对照组各74例,对照组给予阿托伐他汀治疗,观察组给予参麦注射液和阿托伐他汀联合治疗。观察两组患者血脂水平、血清生化指标、临床疗效以及不良反应。结果:治疗2个疗程后,观察组TC、TG、LDL-C、HDL-C及apo B水平较治疗前和对照组均显著下降(P<0.05),而apo A与Lp A水平较治疗前和对照组均显著上升(P<0.05),观察组血清hs-CRP、ET和MMP-9水平水平较治疗前和对照组均显著下降(P<0.05),观察组住院期间病死率、心衰发生率、休克发生率、再梗发生率显著低于对照组,而冠脉再通率显著高于对照组(P<0.05)。结论:参麦注射液联合阿托伐他汀治疗急性心肌梗死疗效肯定,值得临床推广。
Objective: To investigate the clinical efficacy of Shenmai injection combined with atorvastatin in the treatment of acute myocardial infarction. Methods: A total of 148 elderly patients with acute cerebral infarction were randomly divided into observation group (74 cases) and control group (74 cases). The control group was treated with atorvastatin. The observation group was given Shenmai injection combined with atorvastatin. Blood lipid levels, serum biochemical parameters, clinical efficacy and adverse reactions were observed in two groups. Results: After 2 courses of treatment, the levels of TC, TG, LDL-C, HDL-C and apo B in the observation group were significantly lower than those before treatment and in the control group (P <0.05), while the levels of apo A and Lp A (P <0.05). The serum levels of hs-CRP, ET and MMP-9 in the observation group were significantly lower than those before treatment and in the control group (P <0.05). The mortality, heart failure The incidence, the incidence of shock and the incidence of re-infarction were significantly lower than those in the control group, while the rate of coronary recanalization was significantly higher than that in the control group (P <0.05). Conclusion: Shenmai injection combined with atorvastatin in the treatment of acute myocardial infarction with certain effect, worthy of clinical promotion.